lobbying_filings_raw: 4d75b65f-b4e2-45fe-8aec-4768260ef9ef
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4d75b65f-b4e2-45fe-8aec-4768260ef9ef | Q3 | 24486 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 132319 | INOVIO PHARMACEUTICALS | 2019 | third_quarter | 2019-10-14T11:12:30.147000-04:00 | 30000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/4d75b65f-b4e2-45fe-8aec-4768260ef9ef/", "filing_uuid": "4d75b65f-b4e2-45fe-8aec-4768260ef9ef", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2019, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/4d75b65f-b4e2-45fe-8aec-4768260ef9ef/print/", "filing_document_content_type": "text/html", "income": "30000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Frank J. Donatelli, Senior Advisor", "dt_posted": "2019-10-14T11:12:30.147000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "2001 K Street, NW; Suite 400", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20006", "registrant": {"id": 24486, "url": "https://lda.senate.gov/api/v1/registrants/24486/", "house_registrant_id": 33788, "name": "MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP)", "description": "â\u20ac\u2039Public Affairs Government Relations Services", "address_1": "888 16th Street, N.W.; Suite 500", "address_2": null, "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20006", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "RYAN M. BERNSTEIN", "contact_telephone": "+1 202-857-2909", "dt_updated": "2026-01-20T11:52:39.295430-05:00"}, "client": {"id": 132319, "url": "https://lda.senate.gov/api/v1/clients/132319/", "client_id": 1004125, "name": "INOVIO PHARMACEUTICALS", "general_description": "Pharmaceuticals", "client_government_entity": false, "client_self_select": null, "state": "PA", "state_display": "Pennsylvania", "country": "US", "country_display": "United States of America", "ppb_state": "PA", "ppb_state_display": "Pennsylvania", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2020-04-01"}, "lobbying_activities": [{"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 65471, "prefix": null, "prefix_display": null, "first_name": "ROBERT", "nickname": null, "middle_name": null, "last_name": "WASINGER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | DC | US | 33788 | PA | PA | US | US | Pharmaceuticals | 0 | 0 | 1876 | normalized_name | 0.7 |